Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones
- 1 January 2002
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (1) , 51-55
- https://doi.org/10.1016/s0960-894x(01)00678-3
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A 2Bioorganic & Medicinal Chemistry Letters, 2001
- Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic targetCurrent Opinion in Pharmacology, 2001
- N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2Bioorganic & Medicinal Chemistry Letters, 2000
- Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart DiseaseNew England Journal of Medicine, 2000
- Current and future treatment of hyperlipidemia: the role of statinsThe American Journal of Cardiology, 1998
- ChemInform Abstract: Solution-Phase Parallel Synthesis Using Ion-Exchange Resins.ChemInform, 1998
- Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density LipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 1996